Lupin has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation.
Lupin's Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Testosterone Topical Solution, 30 mg per actuation, had annual sales of approximately $244.2 million in the US. (IMS MAT June 2017).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
